A detailed history of Huntington National Bank transactions in United Therapeutics Corp stock. As of the latest transaction made, Huntington National Bank holds 12 shares of UTHR stock, worth $3,822. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12
Previous 55 78.18%
Holding current value
$3,822
Previous $12,000 83.33%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

SELL
$210.76 - $249.51 $9,062 - $10,728
-43 Reduced 78.18%
12 $2,000
Q4 2023

Feb 07, 2024

BUY
$214.88 - $256.94 $214 - $256
1 Added 1.85%
55 $12,000
Q3 2023

Nov 08, 2023

SELL
$211.82 - $248.24 $211 - $248
-1 Reduced 1.82%
54 $12,000
Q2 2023

Aug 11, 2023

BUY
$205.19 - $232.99 $3,898 - $4,426
19 Added 52.78%
55 $12,000
Q1 2023

May 10, 2023

SELL
$212.99 - $276.17 $11,075 - $14,360
-52 Reduced 59.09%
36 $8,000
Q4 2022

Feb 09, 2023

SELL
$205.95 - $280.43 $823 - $1,121
-4 Reduced 4.35%
88 $24,000
Q3 2022

Nov 07, 2022

BUY
$203.3 - $244.17 $13,011 - $15,626
64 Added 228.57%
92 $19,000
Q2 2022

Aug 09, 2022

SELL
$174.81 - $241.14 $349 - $482
-2 Reduced 6.67%
28 $7,000
Q1 2022

May 10, 2022

BUY
$166.16 - $213.96 $166 - $213
1 Added 3.45%
30 $5,000
Q4 2021

Jan 21, 2022

BUY
$184.32 - $216.08 $5,345 - $6,266
29 New
29 $6,000
Q3 2019

Nov 01, 2019

SELL
$74.85 - $85.99 $44,086 - $50,648
-589 Closed
0 $0
Q3 2018

Oct 18, 2018

SELL
$113.81 - $129.46 $2,617 - $2,977
-23 Reduced 3.76%
589 $75,000
Q2 2018

Jul 19, 2018

SELL
$101.14 - $118.31 $809 - $946
-8 Reduced 1.29%
612 $69,000
Q1 2018

Apr 30, 2018

SELL
$107.21 - $151.94 $2,144 - $3,038
-20 Reduced 3.13%
620 $70,000
Q3 2017

Oct 24, 2017

BUY
$114.6 - $136.81 $73,344 - $87,558
640
640 $75,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $14.5B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Huntington National Bank Portfolio

Follow Huntington National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Huntington National Bank with notifications on news.